Statins ameliorate glomerular permeability changes in streptozotocin- induced diabetic rats

American Journal of Therapeutics

Volumn 14, Issue 1, 2007, Pages 41-45

  Mooradian, Arshag D ^a,b   Haas, Michael J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Creatinine; Dyslipidemia; HMG CoA reductase inhibitors; Nephropathy; Streptozotocin

Indexed keywords

CREATININE; DEXTRAN; DRINKING WATER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; ROSUVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; EXPERIMENTAL RAT; GLOMERULUS FILTRATION; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; TREATMENT DURATION; URINALYSIS;

ANIMALS; CREATININE; DEXTRANS; DIABETES MELLITUS, EXPERIMENTAL; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEVALONIC ACID; MOLECULAR WEIGHT; PYRIMIDINES; RATS; RATS, INBRED F344; SIMVASTATIN; STREPTOZOCIN; SULFONAMIDES;

EID: 33847130131     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000245236.88942.fb     Document Type: Article

References (20)

1. Mooradian AD, Haas MJ, Batejko O, et al. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of steptozotocin induced diabetic rats. Diabetes. 2005;54:2977-2982.
2. Skyler JS. Microvascular complications. Retinopathy and nephropathy. Endocrinol Metab Clin North Am. 2001;30:833-856.
3. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exper Clin Endocrinol Diab. 2001;109(Suppl 2):S424-S437.
4. American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S79-S83.
5. Athyros VG, Papageorgiou AA, Elisaf M, et al.; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin. 2003;19:615-617.
6. Lam KS, Cheng IK, Janus ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 1995;38:604-609.
7. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology. 2002;53:493-502.
8. Imai Y, Suzuki H, Saito T, et al. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clin Exp Hypertens. 1999;21:1345-1355.
9. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-2016.
10. Remuzzi A, Puntorieri S, Battaglia C, et al. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest. 1990;85:541-549.
11. Mooradian, AD. Altered chromatin structure of cerebral nuclei in experimental diabetes mellitus. Proc Soc Exp Biol Med. 1992;199:282-286.
12. Hultstrom D, Malmgren L, Gilstring D, et al. FITC-Dextrans as tracers for macromolecular movements in the nervous system. Acta Neuropathol. 1983;59:53-62.
13. Kurusu A, Shou I, Nakamura S, et al. Effects of the new hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 2000;27:767-770.
14. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
15. Carbajal JM, Schaeffer RC Jr. RhoA inactivation enhances endothelial barrier function. Am J Physiol. 1999;277:C955-C964.
16. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002;39:319-27.
17. Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Intl. 2000;58:1420-1430.
18. Haas MJ, Horani MH, Parseghian SA, et al. Statins prevent dextrose-induced endothelial barrier dysfunction possibly through inhibition of superoxide formation. Diabetes. 2006;55:474-479.
19. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation. 2004;110:886-92.
20. Qin J, Zhang Z, Liu J, et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Intl. 2003;64:565-571.